A firm based in Europe raised a second fund with €60M under management for Pre-Seed, Seed, and Series A investments. The fund is backed by a majority of private investors with the support of a number of institutional investors such as European Investment Fund (EIF). The firm invests €1-2M as a seed investment in the form of equity or convertible notes to help companies advance into preclinical proof of concept and can continue investing up to €6M. If additional funds are needed, the firm seeks co-investments from the strong network of investors they have in Europe. The firm is looking for investments across Europe.
The firm invests in the biotech sector, exclusively in the drug development space, and with a preference for Advanced Therapies and Synthetic Biology. The firm has an interest in cutting edge technology, and it specializes in tech transfer opportunities. The firm is agnostic indication-wise and will invest in projects in preclinical stage that have reached an in vivo proof of concept in an animal model relevant for the disease for which the therapy is being developed.
The firm looks for companies with a scientific founder, and preferably a C-Level executive with a track record in biotech or pharmaceutical companies. The firm prefers to lead or co-lead in Seed stage therapeutics companies and will seek a board seat.
If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.
Next Phase Newsletter 
Leave a comment